4'-Methyl-α-pyrrolidinopropiophenone
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H19NO |
| Molar mass | 217.312 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
4'-Methyl-α-pyrrolidinopropiophenone (4-MePPP, MPPP or MαPPP) is a stimulant drug and substituted cathinone. It is structurally very similar to α-PPP, with only one added methyl group in the para position on the phenyl ring. 4-MePPP was sold in Germany as a designer drug in the late 1990s and early 2000s,[2][3][4] along with a number of other pyrrolidinophenone derivatives.[5][6] Although it has never achieved the same international popularity as its better-known relations α-PPP and MDPV, 4-MePPP is still sometimes found as an ingredient of grey-market "bath salt" blends[7] such as "NRG-3".[7]
Legality
[edit]In the United States 4-MePPP is considered a schedule 1 controlled substance as an positional isomer of alpha-pyrrolidinopentiophenone (α-PVP)[8]
See also
[edit]- α-Pyrrolidinopropiophenone (α-PPP)
- 4'-Methoxy-α-pyrrolidinopropiophenone (MOPPP)
- 3,4-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP)
- 3',4'-Methylenedioxy-α-pyrrolidinobutiophenone (MDPBP)
References
[edit]- ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara" [Cannabinoids are proposed to be classified as a health hazard]. Folkhälsomyndigheten [The Public Health Authority] (in Swedish). Retrieved 29 June 2015.
- ^ Springer D, Peters FT, Fritschi G, Maurer HH (June 2002). "Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 773 (1): 25–33. doi:10.1016/S1570-0232(01)00578-5. PMID 12015267.
- ^ Springer D, Paul LD, Staack RF, Kraemer T, Maurer HH (August 2003). "Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes". Drug Metabolism and Disposition. 31 (8): 979–982. doi:10.1124/dmd.31.8.979. PMID 12867484.
- ^ Springer D, Fritschi G, Maurer HH (November 2003). "Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 796 (2): 253–266. doi:10.1016/j.jchromb.2003.07.008. PMID 14581066.
- ^ Maurer HH, Kraemer T, Springer D, Staack RF (April 2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic Drug Monitoring. 26 (2): 127–131. doi:10.1097/00007691-200404000-00007. PMID 15228152. S2CID 9255084.
- ^ Staack RF, Maurer HH (June 2005). "Metabolism of designer drugs of abuse". Current Drug Metabolism. 6 (3): 259–274. doi:10.2174/1389200054021825. PMID 15975043.
- ^ a b Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J (September 2011). "Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones". Drug Testing and Analysis. 3 (9): 569–575. doi:10.1002/dta.204. PMID 21960541.
- ^ "Lists of: Scheduling Actions Controlled Substances Regulated Chemicals" (PDF). U.S. Department of Justice. February 2023. Retrieved 5 March 2023.
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |